Summary:
To evaluate the efficacy, safety, and tolerability of cariprazine 1.5 mg/day and 3 mg/day compared with placebo as an adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have had an inadequate response to antidepressants alone
Qualified Participants Must:
• Male or female 18 to 65 years of age
•
Have an ongoing inadequate response to an anti-depressant treatment
Qualified Participants May Receive:
Compensation for time and travel upon completed visits